Display options
Share it on

Oncoimmunology. 2017 May 11;6(8):e1320630. doi: 10.1080/2162402X.2017.1320630. eCollection 2017.

Umbilical cord blood CD34.

Oncoimmunology

Janneke S Hoogstad-van Evert, Jeannette Cany, Dirk van den Brand, Manon Oudenampsen, Roland Brock, Ruurd Torensma, Ruud L Bekkers, Joop H Jansen, Leon F Massuger, Harry Dolstra

Affiliations

  1. Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands.
  2. Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, the Netherlands.
  3. Department of Biochemistry, Radboud University Medical Center, Nijmegen, the Netherlands.
  4. Department of Tumor Immunology, Radboud University Medical Center, Nijmegen, the Netherlands.

PMID: 28919991 PMCID: PMC5593716 DOI: 10.1080/2162402X.2017.1320630

Abstract

Adoptive transfer of allogeneic natural killer (NK) cells is an attractive therapy approach against ovarian carcinoma. Here, we evaluated the potency of highly active NK cells derived from human CD34+ haematopoietic stem and progenitor cells (HSPC) to infiltrate and mediate killing of human ovarian cancer spheroids using an

Keywords: Adoptive immunotherapy; NK cells; mouse ovarian cancer xenograft; ovarian cancer; tumor spheroid infiltration

References

  1. Stem Cells Dev. 2015 Dec 15;24(24):2886-98 - PubMed
  2. Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):6488-93 - PubMed
  3. Cancer J. 2015 Nov-Dec;21(6):486-91 - PubMed
  4. Cancer Immunol Immunother. 2017 Jan;66(1):129-140 - PubMed
  5. PLoS One. 2011;6(6):e20740 - PubMed
  6. Front Immunol. 2014 Apr 17;5:176 - PubMed
  7. Biochem Biophys Res Commun. 2012 Oct 19;427(2):373-8 - PubMed
  8. Blood. 2014 Jun 19;123(25):3855-63 - PubMed
  9. Scand J Immunol. 2011 Sep;74(3):244-52 - PubMed
  10. Immunity. 2010 Oct 29;33(4):632-44 - PubMed
  11. Clin Cancer Res. 2016 Feb 1;22(3):596-608 - PubMed
  12. Clin Cancer Res. 2005 Jan 1;11(1):67-72 - PubMed
  13. PLoS One. 2010 Feb 15;5(2):e9221 - PubMed
  14. Immunotherapy. 2011 Dec;3(12):1445-59 - PubMed
  15. BMC Cancer. 2015 May 03;15:351 - PubMed
  16. Cytotherapy. 2011 Jan;13(1):98-107 - PubMed
  17. J Immunol. 2015 Oct 15;195(8):4010-9 - PubMed
  18. PLoS One. 2007 Mar 28;2(3):e326 - PubMed
  19. Front Immunol. 2015 Nov 02;6:543 - PubMed
  20. Cancer Res. 2006 Jun 15;66(12):6387-94 - PubMed
  21. J Immunol. 2011 Feb 1;186(3):1538-45 - PubMed
  22. Proc Natl Acad Sci U S A. 2011 Jun 28;108(26):10656-61 - PubMed
  23. Blood. 2005 Apr 15;105(8):3051-7 - PubMed
  24. PLoS One. 2013 Jun 05;8(6):e64384 - PubMed
  25. Front Biosci (Landmark Ed). 2017 Jan 1;22:370-384 - PubMed
  26. Cytotherapy. 2013 Oct;15(10):1297-306 - PubMed
  27. J Transl Med. 2006 Nov 14;4:49 - PubMed
  28. Nat Methods. 2012 Jun 28;9(7):676-82 - PubMed
  29. J Cancer. 2013;4(1):12-24 - PubMed
  30. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29 - PubMed
  31. BMC Med. 2016 Oct 21;14 (1):163 - PubMed
  32. Cell Transplant. 2011;20(11-12):1731-46 - PubMed
  33. Oncotarget. 2016 Feb 9;7(6):7318-28 - PubMed
  34. Stem Cells Dev. 2004 Jun;13(3):307-14 - PubMed
  35. Oncoimmunology. 2015 Apr 1;4(7):e1017701 - PubMed
  36. Nat Protoc. 2009;4(3):309-24 - PubMed
  37. Stem Cells. 2016 Jan;34(1):93-101 - PubMed
  38. Front Immunol. 2015 Apr 28;6:195 - PubMed
  39. Sci China Life Sci. 2015 Dec;58(12):1288-98 - PubMed
  40. Hum Pathol. 1994 Mar;25(3):263-70 - PubMed

Publication Types